Client - CryoTherapeutics
Cryoenergy to prevent heart attacks
Cardiovascular disease is the biggest killer in the developed world but there are currently no approved interventions to treat the inflamed atherosclerotic plaque in coronary arteries that is a major cause of heart attacks. CryoTherapeutics is developing a treatment which enables interventional cardiologists to treat the inflamed region, to stabilise the plaque and to enhance the vessel healing response – all without the need for a stent.
Special Agent has collaborated with CryoTherapeutics in the design, development, and testing of a system which is able to deliver precisely controlled cryoenergy locally to a region of the coronary artery where atherosclerotic plaque is present.
Using a patented catheter technology and a custom-designed coolant delivery system, this treatment, applied at temperatures of -10° to -20°C, has demonstrated efficacy in preclinical trials and has approval for a first in-human patient pilot study.
